77077-83-9

Upstream product

• 56661-82-6 1-hydroxy-4-methyl-isoquinoline-3-carboxylic acid 
• 66896-70-6 2-iodo-N-(2-propen-1-yl)benzamide 
• 56661-85-9 4-methyl-1-oxo-1H-isothiochromene-3-carboxylic acid 
• 77077-82-8 Benzoic acid 4-methyl-1-oxo-1H-isoquinolin-2-yl ester 
• 3951-95-9 4-bromo-1,2-dihydroisoquinolin-1-one 
• 74-88-4 methyl iodide 
• 88-67-5 2-Iodobenzoic acid 
• 704-80-3 (E)-3-phenyl-2-butenoic acid 
• 704-79-0 3-phenylbut-2-enoic acid 
• 26386-88-9 diphenyl phosphoryl azide 
• 101-81-5 Diphenylmethane 
• 872509-51-8 (E)-3-Phenyl-but-2-enoyl azide 
• 56661-84-8 2-[1-(4-oxo-2-thioxo-thiazolidin-5-yliden)-ethyl]-benzoic acid 
• 577-56-0 2-acetyl-benzoic acid 

Downstream Products

• 444898-37-7 C₃₆H₂₉NO₈ 
• 24188-78-1 1-chloro-4-methylisoquinoline 

Relevant academic research and scientific papers

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R3′, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R′3, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Inhibitors of Hepatitis C Virus

Macrocyclic peptides are disclosed having the general formula: wherein R3, R3′, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C Virus Inhibitors

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C virus inhibitors

Macrocyclic peptides are disclosed having the general formula: wherein R′, R3, R3′, R4, R6, X, Q, and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Novel nucleotide triphosphates as potent P2Y2 agonists

The synthesis and P2Y2 activities of a novel series of nucleoside triphosphates are described. Many of these compounds were potent agonists of the P2Y2 receptor.

Simple synthesis of 4-substituted 1(2H)-isoquinolinones via electrophilic trapping of lithiated mono- and dianion precursors

Synthetic routes have been developed to access 4-substituted 1(2H)-isoquinolinones from readily available precursors. This is achieved via electrophilic trapping of di- and monolithium anions derived from alkyllithium exchange of 4-bromo-1(2H)-isoquinolinones and corresponding 4-bromo-1- methoxyisoquinolines, respectively. Products derived from the latter are then hydrolyzed to the target 4-substituted 1(2H)-isoquinolinones. The methodology has potential application to access 4-substituted 1(2H)-isoquinolinones with additional substituents in either ring. Copyright Taylor & Francis Group, LLC.

Hepatitis C virus inhibitors

The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the function of the NS3 protease (also referred to herein as “serine protease”) encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS3 protease.

Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase

The invention relates to pyridine derivatives of formula (I), wherein the substituents and symbols are defined as indicated in the description, processes for the preparation thereof, their usage in the preparation of a pharmaceutical composition for the treatment of a disease which responds to an inhibition of angiogenesis, and pharmaceutical compositions containing such compounds.

HEPATITIS C VIRUS INHIBITORS

Hepatitis C virus inhibitors are disclosed having the general formula:(I) wherein R1, R2, R3, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds toinhibit HCV are also disclosed.